These findings underscore the potential for further exploration into the mechanisms of epigenetic reprogramming in ESR1 mutant breast cancer, offering a promising avenue for uncovering novel vulnerabilities and therapeutic strategies. The gene discussed is ESR1; the disease is breast carcinoma.